搜索
Lantheus Holdings Inc
LNTH添加自选
106.440USD
+0.240+0.23%
交易中 （美东）报价延迟15分钟
6.93B总市值
25.18市盈率 TTM
关键数据
105.000今开
107.990最高
427.04K成交量
25.18市盈率 TTM
15.94市盈率动
--股息TTM
0.66%换手率
106.200昨收
105.000最低
35.76M成交额
22.17市盈率静
5.71市净率
0.00%股息率 TTM
12.68%ROA
103.89052周最高
0.45量比
312.44M净利润
65.07M总股本
4.2278每股收益TTM
-0.04Beta
23.48%ROE
47.25052周最低
2.82%振幅
61.20%毛利率
6.93B总市值
5.32回报/风险
2.33%风险率
TradingKey Lantheus Holdings Inc股票评分
单位: USD 更新时间: 2026-06-22操作建议
Lantheus Holdings Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在医疗设备与耗材行业排名1/203位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价102.46。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Lantheus Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Lantheus Holdings Inc亮点
亮点风险
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
业绩高增长
公司营业收入稳步增长，连续3年增长18.91%
估值高估
公司最新PE估值25.12，处于3年历史高位
机构减仓
最新机构持股77.80M股，环比减少7.09%
私人资本持仓
明星投资者私人资本持仓，最新持仓市值273.79K
分析师目标
根据
13
位分析师
买入
评级
102.462
目标均价
-1.35%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Lantheus Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Lantheus Holdings Inc简介
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
公司代码LNTH
公司Lantheus Holdings Inc
CEOMarkison (Brian A)
网址https://www.lantheus.com/
相关品种
热门品种
常见问题
Lantheus Holdings Inc(LNTH)的当前股价是多少？
Lantheus Holdings Inc(LNTH)的当前股价是 106.15。
Lantheus Holdings Inc的股票代码是什么？
Lantheus Holdings Inc的股票代码是LNTH。
Lantheus Holdings Inc股票的52周最高点是多少？
Lantheus Holdings Inc股票的52周最高点是103.89。
Lantheus Holdings Inc股票的52周最低点是多少？
Lantheus Holdings Inc股票的52周最低点是47.25。
Lantheus Holdings Inc的市值是多少？
Lantheus Holdings Inc的市值是6.91B。
现在Lantheus Holdings Inc(LNTH)的股票是买入、持有还是卖出？
根据分析师评级，Lantheus Holdings Inc(LNTH)的总体评级为买入，目标价格为102.46。
Lantheus Holdings Inc(LNTH)股票的每股收益（EPS TTM）是多少
Lantheus Holdings Inc(LNTH)股票的每股收益（EPS TTM）是3.46。
